GOSS News and Press, Gossamer Bio Inc. From 11/12/19

– Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck to evaluate KEYTRUDA ® (pembrolizumab) in combination with GB1275 in advanced solid tumors – – Company to host confe...

– Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – – Preclinical data for GB1275 fe...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company’...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’...

- First-in-human Phase 1/2 trial of GB1275 to be featured in trial-in-progress poster - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inf...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2019 financial re...

I decided to finalize my bearish thesis on Gossamer Bio ( GOSS ) and put it all in one article. Gossamer Bio, Inc. is San Diego based biotech start-up. The lead drug candidate of the company, GB001 , is being evaluated at Phase-2b for the treatment of moderate-to-severe eosinophilic asthm...

Cellectis S.A. (NASDAQ: CLLS ) resumed with Buy rating and $28 (151% upside) price target at Guggenheim. Shares up  3%  premarket. More news on: Cellectis S.A., Gossamer Bio, Inc., Health Catalyst, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Most investors know what they're getting into when buying a stake in an early-stage pharmaceutical company. Anyone needing a reminder only has to look at the stock chart of Gossamer Bio (NASDAQ: GOSS) .  The company raised $291 million from an initial public offering (IPO) in February...

Shares of Gossamer Bio (NASDAQ: GOSS) fell as much as 14.6% at the market open on Tuesday, then soared as much as 21.4% less than an hour later. The biotech stock was up by 6.7% as of 11:20 a.m. EDT. Why such wild swings?  Novartis (NYSE: NVS) announced that its experimental asthma ...